Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells $488,573.43 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 18,959 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $25.77, for a total value of $488,573.43. Following the completion of the sale, the chief financial officer now owns 132,578 shares in the company, valued at $3,416,535.06. This represents a 12.51 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, November 25th, Oluyemi Okupe sold 101,993 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.62, for a total value of $3,021,032.66.
• On Wednesday, November 13th, Oluyemi Okupe sold 142,886 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.93, for a total value of $4,276,577.98.
• On Monday, October 14th, Oluyemi Okupe sold 269,739 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.31, for a total transaction of $5,478,399.09.
• On Monday, October 7th, Oluyemi Okupe sold 9,868 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.96, for a total transaction of $196,965.28.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $28.15 on Wednesday. Hims & Hers Health, Inc. has a 52-week low of $8.09 and a 52-week high of $35.02. The firm has a market cap of $6.15 billion, a price-to-earnings ratio of 63.98 and a beta of 1.25. The business’s fifty day moving average is $25.92 and its 200-day moving average is $21.31.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.04) earnings per share. As a group, research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

HIMS has been the topic of several research analyst reports. Canaccord Genuity Group increased their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a report on Monday, December 2nd. Bank of America lowered Hims & Hers Health from a “buy” rating to an “underperform” rating and lowered their target price for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th. Morgan Stanley started coverage on Hims & Hers Health in a research note on Tuesday, December 17th. They issued an “overweight” rating and a $42.00 price target for the company. Piper Sandler reiterated a “neutral” rating and set a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $22.80.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors have recently added to or reduced their stakes in HIMS. Renaissance Technologies LLC boosted its position in Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock valued at $121,936,000 after buying an additional 3,205,108 shares in the last quarter. State Street Corp lifted its stake in shares of Hims & Hers Health by 4.7% in the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after acquiring an additional 206,078 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Hims & Hers Health by 12.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock valued at $79,029,000 after acquiring an additional 482,177 shares in the last quarter. Wellington Management Group LLP grew its position in Hims & Hers Health by 34.5% during the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock worth $63,446,000 after acquiring an additional 883,230 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Hims & Hers Health by 15.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock worth $30,714,000 after purchasing an additional 218,566 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.